BioSpace News Archive

PumasAI, a pioneering organization at the forefront of transforming data into life-saving decisions with remarkable speed, is proud to announce the appointment of two distinguished leaders to its team.

Gold Colloid Co., a leading distributor of medical and diagnostic products in the United States, announced today a strategic partnership with Hangzhou Clongene Biotech Co., Ltd., a renowned Chinese manufacturer of in-vitro diagnostic (IVD) rapid tests and raw materials.

BioInvent International AB announced that its early discovery partner Exelixis, Inc. has provided a notice of termination for the option and license agreement for novel antibodies for use in immuno-oncology therapeutics.

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at January 1, 2024.

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of investigational delgocitinib cream and Adbry® data across 10 posters at the upcoming Winter Clinical and Maui Derm conferences this month.

RemeGen Co. Ltd. announced recently that its independently developed mesothelin -targeting antibody-drug conjugate, RC88, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

SimBioSys is pleased to announce the strategic appointment of Dr. Barry Rosen as its Chief Medical Officer.

Nanoscope Therapeutics Inc. today announced that Dr. Samarendra Mohanty, President & Chief Scientific Officer, and Dr. Jared Stephens, Vice President of Strategy & Business Development will be presenting at the 20th Annual Advanced Therapies Week Conference taking place from January 16-19 at the Miami Convention Center in Miami, Florida.

IDEXX Laboratories, Inc. announced the expansion of its Fecal Dx ® antigen testing platform with the addition of Cystoisospora.

Qilian International Holding Group Limited today announced that on January 10, 2024, the Company received a written notification from the Nasdaq’s Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq’s minimum bid price requirement.